Oruka Therapeutics公布Orka-001在中重度斑块状银屑病二期临床试验的积极第16周数据

美股速递
Apr 27

生物制药公司Oruka Therapeutics宣布,其核心候选药物Orka-001在针对中重度斑块状银屑病开展的Everlast二期a阶段临床试验中,第16周随访数据呈现积极结果。

该持续进行的临床研究旨在评估Orka-001的有效性与安全性,最新数据表明,在治疗第16周时,药物在改善患者皮损严重程度方面显示出显著疗效,达到了试验预设的主要终点指标。这一进展为后续临床试验的推进提供了有力支持,也增强了市场对该疗法潜力的信心。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10